Inventiva (NASDAQ:IVA) Shares Gap Down - Should You Sell?

Key Points

• Inventiva S.A. shares experienced a gap down from a previous close of $6.53 to an opening of $6.03 on Monday, reflecting investor concerns.
• Wall Street analysts have mixed reviews on Inventiva, with six rating it as a "Buy" and Weiss Ratings issuing a "Sell (d-)" rating, resulting in a consensus rating of "Moderate Buy" with a target price of $15.57.
• Inventiva is focused on developing treatments for non-alcoholic steatohepatitis (NASH) with its lead product candidate, Lanifibranor, currently in Phase III clinical trials.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $6.53, but opened at $6.03. Inventiva shares last traded at $6.08, with a volume of 46,924 shares.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IVA. HC Wainwright assumed coverage on Inventiva in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $20.00 target price for the company. Guggenheim increased their price objective on Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research report on Saturday, September 27th. Piper Sandler began coverage on shares of Inventiva in a report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $15.57.

Inventiva Price Performance

The firm has a 50-day moving average of $4.90 and a 200-day moving average of $3.86.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.